Sudhir Valia to focus more on pursuits outside Sun, but continues to be a valuable resource for the company.

Shanghvi was responding to the concern raised by some investors whether Aditya Medisales has benefited in the past at the cost of Sun Pharm...

A whistle-blower complaint has alleged that the company reportedly dealt with banned traders.

Sun Pharma’s shares have been volatile in the last two months.

Sun Pharma's domestic formulations biz would be transitioned from Aditya Medisales to a wholly owned arm.

The stock ended at Rs 418 on Tuesday, emerging as the top gainer on the Sensex.

The foreign brokerage said valuations of Sun Pharma are attractive given improving business fundamentals.

The company will make its unit the new distributor for its domestic formulations business.

The company "unequivocally" denied that it had lent or stood guarantee for Suraksha Realty

Sudhir Valia, brother-in-law of Sun Pharma promoter Dilip Shanghvi, in a telephonic chat with Divya Rajagopal, discusses the issues of Adit...

Bloomberg data showed that of the 41 analysts tracking the stock, 22 have 'buy' ratings.

Even if they are not hiding, they are not giving a convincing answer, says Subramanian.

Sun complained that such access creates a "great asymmetry in the information circulating between analysts, investors and media, leading to...

We are not privy to the contents of the document being referred, Sun Pharma said.

“Sun Pharma must say they are not going to have any transaction with Aditya Medisales going forward.”

Currently, the share is trading at around 19 to 20 times and I do not see a downside from there, says Singh.

The lack of disclosures around non-related party transactions to the tune of Rs 2,200 crore has become a sore spot for investors, who are q...